BCL2 and breast cancer: Similar to previous reports [39], the downregulation of Bcl-2, among our cases, was more evident in aggressive subtypes of breast cancer, such as ER- and/or PR- (27%), triple-negative (31%), and Her2+ (14%), compared to ER positive BC tissue.